آدرس ایمیل خود را وارد نمایید
ثبت
پیام خود را بنویسید
جلد 17، شماره 1 - ( مجله علمی بیماری های پستان ایران 1403 )
جلد 17 شماره 1 صفحات 138-116 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salehpour S, Saharkhiz N, Hosseini S, Esmaeili S, Hajizadeh N, Majdi L et al . Fertility Preservation :A Big Dilemma For Patients With Breast Cancer. ijbd 2024; 17 (1) :116-138
URL: http://ijbd.ir/article-1-1101-fa.html
URL: http://ijbd.ir/article-1-1101-fa.html
صالحپور ساغر، سحرخیز نسرین، حسینی صدیقه، اسمعیلی سمانه، حاجی زاده نازنین، مجدی لیلا و همکاران.. حفظ باروری؛ یک معضل بزرگ برای بیماران مبتلا به سرطان پستان. بیماری‌های پستان ایران. 1403; 17 (1) :116-138
ساغر صالحپور1 
، نسرین سحرخیز1 ، صدیقه حسینی1 ، سمانه اسمعیلی* 2، نازنین حاجی زاده1 ، لیلا مجدی1 ، هستی ضیایی3
، نسرین سحرخیز1 ، صدیقه حسینی1 ، سمانه اسمعیلی* 2، نازنین حاجی زاده1 ، لیلا مجدی1 ، هستی ضیایی3
1- مرکز تحقیقات پیشگیری ازبیماریهای زنان و زایمان ، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران
2- مرکز تحقیقات پیشگیری ازبیماریهای زنان و زایمان ، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران ،dresmaeili@gmail.com
3- دانشکده پزشکی، دانشگاه مرکزی لنکاوی، پرستون، انگلستان، انگلستان
2- مرکز تحقیقات پیشگیری ازبیماریهای زنان و زایمان ، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران ،
3- دانشکده پزشکی، دانشگاه مرکزی لنکاوی، پرستون، انگلستان، انگلستان
چکیده: (713 مشاهده)
مقدمه: سرطان پستان ازشایع ترین بدخیمی ها در زنان است. شیمی درمانی سیتوتوکسیک یا هورمون درمانی دارای تأثیر منفی بر پتانسیل باروری هستند. لذا به کارگیری تکنیک هایی همچون سرکوب تخمدان، انجماد تخمک و جنین، بازیابی تخمک نابالغ و بلوغ آزمایشگاهی آن و انجماد بافت تخمدان برای حفظ باروری ضروری است.
روش بررسی: تحقیق مروری ارائه شده براساس اطلاعات به دست آمده از جستجوی منابع فارسی و انگلیسی Scoupus ، Google Scholar، Pub Med، Science Direct طی 24 سال اخیر و با کلیدواژه‌های سرطان پستان، نازایی، حفظ باروری، انجماد تخمک، انجماد جنین انجام شده است.
یافته‌ها: 15% تا25% بیماران، زنان جوان پیش از سن یائسگی هستند. شیمی درمانی یا پرتودرمانی می‌تواند منجر به ناباروری یا یائسگی زودرس شود. با توجه به شواهد، میزان موفقیت انجماد جنین به مراتب نسبت به انجماد تخمک و بازیابی تخمک نابالغ بیشتر است. از بین روشهای حفظ باروری، انجماد بافت تخمدان و پرینت زیستی سه‌بعدی در مرحله تحقیقات آزمایشگاهی بوده و بسیار مورد توجه واقع شده‌اند. مشاوره درست وارائه اطلاعات دقیق به بیمارو ارجاع به‌موقع آن‌ها تأثیر فراوانی بر بهبود وضعیت روانی وجسمی و درمان بیماری زمینه‌ای آن‌ها داشته است.
نتیجه‌گیری: با تشخیص زودهنگام سرطان پستان، ارجاع به هنگام به متخصص باروری،ارائه مشاوره صحیح و روش های نوین کمک باروری، بیماران مبتلابه سرطان پستان پس از درمان‌های تهاجمی سرطان، باروری خود را حفظ و تجربه فرزند بیولوژیک خود را خواهند داشت.
روش بررسی: تحقیق مروری ارائه شده براساس اطلاعات به دست آمده از جستجوی منابع فارسی و انگلیسی Scoupus ، Google Scholar، Pub Med، Science Direct طی 24 سال اخیر و با کلیدواژه‌های سرطان پستان، نازایی، حفظ باروری، انجماد تخمک، انجماد جنین انجام شده است.
یافته‌ها: 15% تا25% بیماران، زنان جوان پیش از سن یائسگی هستند. شیمی درمانی یا پرتودرمانی می‌تواند منجر به ناباروری یا یائسگی زودرس شود. با توجه به شواهد، میزان موفقیت انجماد جنین به مراتب نسبت به انجماد تخمک و بازیابی تخمک نابالغ بیشتر است. از بین روشهای حفظ باروری، انجماد بافت تخمدان و پرینت زیستی سه‌بعدی در مرحله تحقیقات آزمایشگاهی بوده و بسیار مورد توجه واقع شده‌اند. مشاوره درست وارائه اطلاعات دقیق به بیمارو ارجاع به‌موقع آن‌ها تأثیر فراوانی بر بهبود وضعیت روانی وجسمی و درمان بیماری زمینه‌ای آن‌ها داشته است.
نتیجه‌گیری: با تشخیص زودهنگام سرطان پستان، ارجاع به هنگام به متخصص باروری،ارائه مشاوره صحیح و روش های نوین کمک باروری، بیماران مبتلابه سرطان پستان پس از درمان‌های تهاجمی سرطان، باروری خود را حفظ و تجربه فرزند بیولوژیک خود را خواهند داشت.
نوع مطالعه: مروری |
موضوع مقاله:
تشخیص، درمان، بازتوانی
دریافت: 1402/12/12 | پذیرش: 1403/1/18 | انتشار: 1403/2/6
دریافت: 1402/12/12 | پذیرش: 1403/1/18 | انتشار: 1403/2/6
فهرست منابع
1. Get persistent links for your reference list or bibliography.
Copy and paste the list, we’ll match with our metadata and return the links.
Members may also deposit reference lists here too.
1. Lambertini, M.; Del Mastro, L.; Pescio, M. C.; Andersen, C. Y.; Azim, H. A.; Peccatori, F. A, et al. Cancer and fertility preservation: international recommendations from an expert meeting BMC medicine. 2016; 14(1): 1-16. [DOI:10.1186/s12916-015-0545-7] [PMID] []
2. Loren, A. W.; Mangu, P. B.; Beck, L. N.; Brennan, L.; Magdalinski, A. J.; Partridge, A. H, et al. K.Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update Journal of clinical oncology. 2013; 31(19): 2500-10. [DOI:10.1200/JCO.2013.49.2678] [PMID] []
3. Muñoz, M.; Santaballa, A.; Seguí, M.; Beato, C.; De La Cruz, S.; Espinosa, J et al. SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016) Clinical and Translational Oncology. 2016; 18(12): 1229-36. [DOI:10.1007/s12094-016-1587-9] [PMID] []
4. Bhardwaj, J. K.; Bikal, P.; Sachdeva, S. N. Chemotherapeutic drugs induced female reproductive toxicity and treatment strategies Journal of Biochemical and Molecular Toxicology. 2023: e23371. [DOI:10.1002/jbt.23371] [PMID]
5. Spears, N.; Lopes, F.; Stefansdottir, A.; Rossi, V.; De Felici, M.; Anderson, R., et al. F.Ovarian damage from chemotherapy and current approaches to its protection Human reproduction update. 2019; 25(6): 673-93. [DOI:10.1093/humupd/dmz027] [PMID] []
6. Donnez, J.; Dolmans, M.-M.Fertility preservation in women New England Journal of Medicine. 2017; 377(17): 1657-65. [DOI:10.1056/NEJMra1614676] [PMID]
7. Nguyen, Q.; Zerafa, N.; Liew, S.; Findlay, J. K.; Hickey, M.; Hutt, K. Cisplatin-and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes Molecular human reproduction. 2019; 25(8): 433-44. [DOI:10.1093/molehr/gaz020] [PMID]
8. McLaren, J. F.; Bates, G. W. Fertility preservation in women of reproductive age with cancer American journal of obstetrics and gynecology. 2012; 207(6): 455-62. [DOI:10.1016/j.ajog.2012.08.013] [PMID]
9. Kabirian, R.; Franzoi, M. A.; Havas, J.; Coutant, C.; Tredan, O.; Levy, C.; Cottu, P.; et al. Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer JAMA Network Open. 2023; 6(11): e2343910-e2343910. [DOI:10.1001/jamanetworkopen.2023.43910] [PMID] []
10. Bines, J.; Oleske, D. M.; Cobleigh, M. A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer Journal of Clinical Oncology. 1996; 14(5): 1718-29. [DOI:10.1200/JCO.1996.14.5.1718] [PMID]
11. Abusief, M. E.; Missmer, S. A.; Ginsburg, E. S.; Weeks, J. C.; Partridge, A. H. The effects of paclitaxel, dose density, and trastuzumab on treatment‐related amenorrhea in premenopausal women with breast cancer Cancer: Interdisciplinary International Journal of the American Cancer Society. 2010; 116(4): 791-8. [DOI:10.1002/cncr.24835] [PMID]
12. Conte, B.; Del Mastro, L.Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients Minerva ginecologica. 2017; 69(4): 350-6. [DOI:10.23736/S0026-4784.17.04067-9] [PMID]
13. Berliere, M.; Duhoux, F. P.; Dalenc, F.; Baurain, J.-F.; Dellevigne, L.; Galant, C., et al. Tamoxifen and ovarian function PLoS One. 2013; 8(6): e66616. [DOI:10.1371/journal.pone.0066616] [PMID] []
14. Warner, E.; Glass, K.; Foong, S.; Sandwith, E. Update on fertility preservation for younger women with breast cancer Cmaj. 2020; 192(35): E1003-E1009. [DOI:10.1503/cmaj.200245] [PMID] []
15. Mauri, D.; Gazouli, I.; Zarkavelis, G.; Papadaki, A.; Mavroeidis, L.; Gkoura, S.; et al. Chemotherapy associated ovarian failure Frontiers in Endocrinology. 2020; 11: 1-7. [DOI:10.3389/fendo.2020.572388] [PMID] []
16. Poorvu, P. D.; Frazier, A. L.; Feraco, A. M.; Manley, P. E.; Ginsburg, E. S.; Laufer, M. R.; et al. Cancer treatment-related infertility: a critical review of the evidence JNCI Cancer Spectrum. 2019; 3(1): pkz008. [DOI:10.1093/jncics/pkz008] [PMID] []
17. ter Welle-Butalid, M.; Vriens, I.; Derhaag, J.; Leter, E.; de Die-Smulders, C.; Smidt, M.; et al. Counseling young women with early breast cancer on fertility preservation Journal of assisted reproduction and genetics. 2019; 36: 2593-604. [DOI:10.1007/s10815-019-01615-6] [PMID] []
18. Cardoso, F.; Loibl, S.; Pagani, O.; Graziottin, A.; Panizza, P.; Martincich, L.; et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer European journal of cancer. 2012; 48(18): 3355-77. [DOI:10.1016/j.ejca.2012.10.004] [PMID]
19. Sly, J. R.; Miller, S. J.; Thelemaque, L.; Yazdanie, F.; Sperling, R.; Sasan, F.; et al. Knowledge of the relationship between breastfeeding and breast cancer risk among racial and ethnic minority women Journal of Cancer Education. 2020; 35:1193-6. [DOI:10.1007/s13187-019-01580-9] [PMID] []
20. Ulrich, N. D.; Raja, N. S.; Moravek, M. B.A review of fertility preservation in patients with breast cancer Best Practice & Research Clinical Obstetrics & Gynaecology. 2022; 82: 60-8. [DOI:10.1016/j.bpobgyn.2022.01.004] [PMID]
21. Oktay, K.; Harvey, B. E.; Partridge, A. H.; Quinn, G. P.; Reinecke, J.; Taylor, H. S.; et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update Journal of Clinical Oncology. 2018; 36(19): 1994-2001. [DOI:10.1200/JCO.2018.78.1914] [PMID]
22. Cakmak, H.; Katz, A.; Cedars, M. I.; Rosen, M. P. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation Fertility and sterility. 2013; 100(6): 1673-80. [DOI:10.1016/j.fertnstert.2013.07.1992] [PMID]
23. Kim, J. H.; Kim, S. K.; Lee, H. J.; Lee, J. R.; Jee, B. C.; Suh, C. S.; et al. Efficacy of random-start controlled ovarian stimulation in cancer patients Journal of Korean Medical Science. 2015; 30(3): 290-5. [DOI:10.3346/jkms.2015.30.3.290] [PMID] []
24. Razeti, M.; Spinaci, S.; Spagnolo, F.; Massarotti, C.; Lambertini, M. How I perform fertility preservation in breast cancer patients ESMO open. 2021; 6(3): 100112. [DOI:10.1016/j.esmoop.2021.100112] [PMID] []
25. Okutsu-Horage, Y.; Iwahata, H.; Suzuki-Takahashi, Y.; Sugishita, Y.; Takae, S.; Suzuki, N. Clinical outcome of embryo cryopreservation in Japanese breast cancer patients: pregnancy rates after transfer of thawed embryos Journal of Assisted Reproduction and Genetics. 2022; 39(8): 1769-77. [DOI:10.1007/s10815-022-02575-0] [PMID] []
26. Kris, M. G.; Hesketh, P. J.; Somerfield, M. R.; Feyer, P.; Clark-Snow, R.; Koeller, J. M.; et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 Journal of clinical oncology. 2006; 24(18): 2932-47. [DOI:10.1200/JCO.2006.06.9591] [PMID]
27. Massarotti, C.; Scaruffi, P.; Lambertini, M.; Remorgida, V.; Del Mastro, L.; Anserini, P. State of the art on oocyte cryopreservation in female cancer patients: a critical review of the literature Cancer treatment reviews. 2017; 57: 50-7. [DOI:10.1016/j.ctrv.2017.04.009] [PMID]
28. Cobo, A.; García-Velasco, J. A.; Coello, A.; Domingo, J.; Pellicer, A.; Remohí, J. Oocyte vitrification as an efficient option for elective fertility preservation Fertility and sterility. 2016; 105(3): 755-764. e758. [DOI:10.1016/j.fertnstert.2015.11.027] [PMID]
29. Cobo, A.; García-Velasco, J.; Domingo, J.; Pellicer, A.; Remohí, J. Elective and onco-fertility preservation: factors related to IVF outcomes Human reproduction. 2018; 33(12): 2222-31. [DOI:10.1093/humrep/dey321] [PMID]
30. Lambertini, M.; Peccatori, F. A.; Demeestere, I.; Amant, F.; Wyns, C.; Stukenborg, J.-B.; et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines Annals of oncology. 2020; 31(12): 1664-78. [DOI:10.1016/j.annonc.2020.09.006] [PMID]
31. Cheng, J.; Ruan, X.; Du, J.; Jin, F.; Li, Y.; Liu, X.; et al. Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report Journal of Ovarian Research. 2021; 14(1): 1-7. [DOI:10.1186/s13048-021-00929-3] [PMID] []
32. Anderson, R. A.; Amant, F.; Braat, D.; D'Angelo, A.; Chuva de Sousa Lopes, S. M.; Demeestere, I.; et al. ESHRE guideline: female fertility preservation Hum Reprod Open. 2020; 2020(4): hoaa052. DOI: 10.1093/hropen/hoaa052 From NLM. [DOI:10.1093/hropen/hoaa052] [PMID] []
33. Donnez, J.; Dolmans, M.-M.Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice Journal of assisted reproduction and genetics. 2015; 32: 1167-70. [DOI:10.1007/s10815-015-0544-9] [PMID] []
34. Kim, H.; Kim, S. K.; Lee, J. R.; Hwang, K. J.; Suh, C. S.; Kim, S. H. Fertility preservation for patients with breast cancer: The Korean Society for Fertility Preservation clinical guidelines Clinical and experimental reproductive medicine. 2017; 44(4): 181-6. [DOI:10.5653/cerm.2017.44.4.181] [PMID] []
35. Bigorie, V.; Morice, P.; Duvillard, P.; Antoine, M.; Cortez, A.; Flejou, J. F.; et al. Ovarian metastases from breast cancer: report of 29 cases Cancer: Interdisciplinary International Journal of the American Cancer Society. 2010; 116(4): 799-804. [DOI:10.1002/cncr.24807] [PMID]
36. Lambertini, M.; Boni, L.; Michelotti, A.; Magnolfi, E.; Cogoni, A. A.; Mosconi, A. M.; et al. Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients JNCI: Journal of the National Cancer Institute. 2022; 114(3): 400-8. [DOI:10.1093/jnci/djab213] [PMID] []
37. Lambertini, M.; Horicks, F.; Del Mastro, L.; Partridge, A. H.; Demeestere, I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application Cancer treatment reviews. 2019; 72:65-77. [DOI:10.1016/j.ctrv.2018.11.006] [PMID]
38. Kim, H. J.; Lee, M. H.; Lee, J. E.; Park, S.; Lee, E. S.; Kang, Y. J et al. Oncologic safety of gonadotropin-releasing hormone agonist for ovarian function protection during breast cancer chemotherapy Clinical Breast Cancer. 2018; 18(5): e1165-e1172. [DOI:10.1016/j.clbc.2018.04.008] [PMID]
39. Blumenfeld, Z.How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries The oncologist. 2007; 12(9): 1044-54. [DOI:10.1634/theoncologist.12-9-1044] [PMID]
40. Lambertini, M.; Richard, F.; Nguyen, B.; Viglietti, G.; Villarreal-Garza, C. Ovarian function and fertility preservation in breast cancer: should gonadotropin-releasing hormone agonist be administered to all premenopausal patients receiving chemotherapy? Clinical Medicine Insights: Reproductive Health. 2019; 13: 1179558119828393. [DOI:10.1177/1179558119828393] [PMID] []
41. Del Mastro, L.; Ceppi, M.; Poggio, F.; Bighin, C.; Peccatori, F.; Demeestere, I et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials Cancer treatment reviews. 2014; 40(5): 675-83. [DOI:10.1016/j.ctrv.2013.12.001] [PMID]
42. Lambertini, M.; Ceppi, M.; Poggio, F.; Peccatori, F. A.; Azim Jr, H.; Ugolini, D et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies Annals of Oncology. 2015; 26 (12): 2408-19. [DOI:10.1093/annonc/mdv374] [PMID]
43. Munhoz, R. R.; Pereira, A. A.; Sasse, A. D.; Hoff, P. M.; Traina, T. A.; Hudis, C. A.; et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis JAMA oncology. 2016; 2(1): 65-73. [DOI:10.1001/jamaoncol.2015.3251] [PMID] []
44. Khalili, M.A.; Shahedi, A.; Ashourzadeh, S.; Nottola, S.A.; Macchiarelli, G.; Palmerini, M.G. Vitrification of human immature oocytes before and after in vitro maturation: A review. J. Assist. Reprod. Genet. 2017; 34: 1413-26. [DOI:10.1007/s10815-017-1005-4] [PMID] []
45. Wu, T.; Gao, Y.Y.; Su, J.; Tang, X.N.; Chen, Q.; Ma, L.W.; et al. Three-dimensional bioprinting of artificial ovaries by an extrusion-based method using gelatin-methacryloyl bioink. Climacteric. 2022; 25: 170-8. [DOI:10.1080/13697137.2021.1921726] [PMID]
46. Lambertini, M.; Blondeaux, E.; Bruzzone, M.; Perachino, M.; Anderson, R. A.; de Azambuja, E.; et al. Pregnancy after breast cancer: a systematic review and meta-analysis Journal of Clinical Oncology. 2021; 39(29): 3293-305. [DOI:10.1200/JCO.21.00535] [PMID]
47. Souchon, R.Pregnancy following breast cancer: results of a systematic review and meta-analysis Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft...[et al]. 2022; 198(8): 761-3. [DOI:10.1007/s00066-022-01949-8] [PMID]
48. Kranick, J. A.; Schaefer, C.; Rowell, S.; Desai, M.; Petrek, J. A.; Hiatt, R. A.; et al. Is pregnancy after breast cancer safe? The breast journal. 2010; 16(4): 404-11. [DOI:10.1111/j.1524-4741.2010.00939.x] [PMID] []
49. Ives, A.; Saunders, C.; Bulsara, M.; Semmens, J.Pregnancy after breast cancer: population based study Bmj. 2007; 334(7586): 194-6. [DOI:10.1136/bmj.39035.667176.55] [PMID] []
50. Azim Jr, H. A.; Kroman, N.; Paesmans, M.; Gelber, S.; Rotmensz, N.; Ameye, L.; et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study Journal of clinical oncology. 2013; 31(1): 73-9. [DOI:10.1200/JCO.2012.44.2285] [PMID] []
51. Santoro, L.; Pavlidis, N.; Gelber, S.; Kroman, N.; Azim, H. A.; Peccatori, F. A. Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies. 2011;47(1): 74-83. [DOI:10.1016/j.ejca.2010.09.007] [PMID]
52. Pagani, O.; Partridge, A.; Korde, L.; Badve, S.; Bartlett, J.; Albain, K.; et al. Pregnancy after breast cancer: if you wish, ma'am Breast cancer research and treatment. 2011; 129: 309-17. [DOI:10.1007/s10549-011-1643-7] [PMID]
53. von Schoultz, E.; Johansson, H.; Wilking, N.; Rutqvist, L.-E. Influence of prior and subsequent pregnancy on breast cancer prognosis Journal of clinical oncology. 1995; 13(2): 430-4. [DOI:10.1200/JCO.1995.13.2.430] [PMID]
54. Upponi, S.; Ahmad, F.; Whitaker, I.; Purushotham, A.Pregnancy after breast cancer European Journal of Cancer. 2003; 39(6): 736-41. [DOI:10.1016/S0959-8049(02)00870-5] [PMID]
55. Helewa, M.; Levesque, P.; Provencher, D.; Lea, R. H.; Rosolowich, V.; Shapiro, H. M. Breast cancer, pregnancy, and breastfeeding Journal of obstetrics and gynaecology Canada: JOGC= Journal d'obstetrique et gynecologie du Canada: JOGC. 2002; 24(2): 164-80.
56. De Pedro, M.; Otero, B.; Martín, B. Fertility preservation and breast cancer: a review ecancermedicalscience. 2015; 9: 503-10. [DOI:10.3332/ecancer.2015.503] [PMID] []
57. Elliott, P. Pathogenesis of cardiotoxicity induced by anthracyclines Semin Oncol. 2006; 33: 2-7. [DOI:10.1053/j.seminoncol.2006.04.020] [PMID]
58. Dalberg, K.; Eriksson, J.; Holmberg, L. Birth outcome in women with previously treated breast cancer-a population-based cohort study from Sweden PLoS medicine. 2006; 3(9): e336. [DOI:10.1371/journal.pmed.0030336] [PMID] []
59. Leproux, C.; Seegers, V.; Patsouris, A.; Sauterey, B. Success and risks of pregnancy after breast cancer Breast Cancer Research and Treatment. 2021; 188: 593-600. [DOI:10.1007/s10549-021-06232-5] [PMID]
60. Gerstl, B.; Sullivan, E.; Ives, A.; Saunders, C.; Wand, H.; Anazodo, A. Pregnancy outcomes after a breast cancer diagnosis: a systematic review and meta-analysis Clinical breast cancer. 2018; 18 (1): e79-e88. [DOI:10.1016/j.clbc.2017.06.016] [PMID]
61. Dow, K. H.; Kuhn, D. Fertility options in young breast cancer survivors: a review of the literature. In Oncology nursing forum. 2004; 31(3):E46-53. [DOI:10.1188/04.ONF.E46-E53] [PMID]
62. van Dalen, E. C.; van der Pal, H. J.; van den Bos, C.; Kok, W. E.; Caron, H. N.; Kremer, L. C. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines European Journal of Cancer. 2006; 42(15): 2549-53. [DOI:10.1016/j.ejca.2006.04.014] [PMID]
63. Seynaeve, C.; Verhoog, L.; van de Bosch, L.; Van Geel, A.; Menke-Pluymers, M.; Meijers-Heijboer, E.; et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy European Journal of Cancer. 2004; 40(8): 1150-8. [DOI:10.1016/j.ejca.2004.01.017] [PMID]
64. Kotsopoulos, J.BRCA mutations and breast cancer prevention Cancers. 2018; 10(12): 524-39. [DOI:10.3390/cancers10120524] [PMID] []
65. Haffty, B. G.; Harrold, E.; Khan, A. J.; Pathare, P.; Smith, T. E.; Turner, B. C.; et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status The Lancet. 2002; 359(9316): 1471-7. [DOI:10.1016/S0140-6736(02)08434-9] [PMID]
66. Varol, U.; Kucukzeybek, Y.; Alacacioglu, A.; Somali, I.; Altun, Z.; Aktas, S et al. Brca genes: brca 1 and brca 2 apoptosis. 2018; 13(19): 862-6.
67. Metcalfe, K.; Lynch, H. T.; Ghadirian, P.; Tung, N.; Olivotto, I.; Warner, E.; et al..Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers Journal of Clinical Oncology. 2004; 22(12): 2328-35. [DOI:10.1200/JCO.2004.04.033] [PMID]
68. King, M.-C.; Marks, J. H.; Mandell, J. B.Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science. 2003; 302(5645): 643-6. [DOI:10.1126/science.1088759] [PMID]
69. Casaubon, J. T.; Kashyap, S.; Regan, J. P. BRCA1 and BRCA2 Mutations. In StatPearls, 2024.
70. Antoniou, A.; Pharoah, P. D.; Narod, S.; Risch, H. A.; Eyfjord, J. E.; Hopper, J. L.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies The American Journal of Human Genetics. 2003; 72(5): 1117-30. [DOI:10.1086/375033] [PMID] []
71. Ford, D.; Easton, D. F.; Bishop, D. T.; Narod, S. A.; Goldgar, D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Lancet. 1994; 343(8899): 692-5. [DOI:10.1016/S0140-6736(94)91578-4] [PMID]
72. Engel, C.; Fischer, C.; Zachariae, S.; Bucksch, K.; Rhiem, K.; Giesecke, J.; et al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance International journal of cancer. 2020; 146(4): 999-1009. [DOI:10.1002/ijc.32396] [PMID]
73. Rebbeck, T. R.; Lynch, H. T.; Neuhausen, S. L.; Narod, S. A.; Van't Veer, L.; Garber, J. E.; et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations New England Journal of Medicine. 2002; 346(21): 1616-22. [DOI:10.1056/NEJMoa012158] [PMID]
74. Kauff, N. D.; Domchek, S. M.; Friebel, T. M.; Robson, M. E.; Lee, J.; Garber, J. E.; et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study Journal of clinical oncology. 2008; 26(8): 1331-7. [DOI:10.1200/JCO.2007.13.9626] [PMID] []
75. Jernström, H.; Lerman, C.; Ghadirian, P.; Lynch, H. T.; Weber, B.; Garber, J.; et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 The Lancet. 1999; 354(9193): 1846-50. [DOI:10.1016/S0140-6736(99)04336-6] [PMID]
76. Oktay, K.; Kim, J. Y.; Barad, D.; Babayev, S. N. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks Journal of Clinical Oncology. 2010; 28(2): 240-4. [DOI:10.1200/JCO.2009.24.2057] [PMID] []
77. Rzepka-Górska, I.; Tarnowski, B.; Chudecka-Głaz, A.; Górski, B.; Zielińska, D.; Tołoczko-Grabarek, A. Premature menopause in patients with BRCA1 gene mutation Breast cancer research and treatment. 2006; 100:59-63. [DOI:10.1007/s10549-006-9220-1] [PMID]
78. Andrieu, N.; Goldgar, D. E.; Easton, D. F.; Rookus, M.; Brohet, R.; Antoniou, A. C.; et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) Journal of the National Cancer Institute. 2006; 98(8): 535-44. [DOI:10.1093/jnci/djj132] [PMID] []
79. Antoniou, A. C.; Shenton, A.; Maher, E. R.; Watson, E.; Woodward, E.; Lalloo, F.; et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers Breast Cancer Research. 2006; 8: 1-6. [DOI:10.1186/bcr1630] [PMID] []
80. Oktay, K.; Economos, K.; Kan, M.; Rucinski, J.; Veeck, L.; Rosenwaks, Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm Jama 2001. 286(12): 1490-3. [DOI:10.1001/jama.286.12.1490] [PMID]
81. Oktay, K.; Buyuk, E.; Veeck, L.; Zaninovic, N.; Xu, K.; Takeuchi, T.; et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue The Lancet. 2004; 363(9412): 837-40. [DOI:10.1016/S0140-6736(04)15728-0] [PMID]
82. Fortuny, D.; Balmana, J.; Grana, B.; Torres, A.; Cajal, T. R. y.; Darder, E.; et al. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort Human Reproduction. 2009; 24(4): 1000-6. [DOI:10.1093/humrep/den471] [PMID]
83. Ormondroyd, E.; Donnelly, L.; Moynihan, C.; Savona, C.; Bancroft, E.; Evans, D. G.; et al. Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis European Journal of Human Genetics. 2012; 20(1): 4-10. [DOI:10.1038/ejhg.2011.146] [PMID] []
84. Armuand, G. M.; Rodriguez-Wallberg, K. A.; Wettergren, L.; Ahlgren, J.; Enblad, G.; Höglund, M.; et al. Sex differences in fertility-related information received by young adult cancer survivors Journal of Clinical Oncology. 2012; 30(17): 2147-53. [DOI:10.1200/JCO.2011.40.6470] [PMID]
85. Berger, J. C.; Clericuzio, C. L. Pierre Robin sequence associated with first trimester fetal tamoxifen exposure American Journal of Medical Genetics Part A. 2008; 146(16): 2141-4. [DOI:10.1002/ajmg.a.32432] [PMID]
86. Lambertini, M.; Kroman, N.; Ameye, L.; Cordoba, O.; Pinto, A.; Benedetti, G.; et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status JNCI: Journal of the National Cancer Institute. 2018; 110(4): 426-9. [DOI:10.1093/jnci/djx206] [PMID] []
87. Lalami, I.; Labrosse, J.; Cedrin-Durnerin, I.; Comtet, M.; Vinolas, C.; Krief, F.; et al. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? Reproductive Biology and Endocrinology. 2022; 20(1): 1-8. [DOI:10.1186/s12958-022-00958-7] [PMID] []
88. Sonigo, C.; Sermondade, N.; Calvo, J.; Benard, J.; Sifer, C.; Grynberg, M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients European Journal of Obstetrics & Gynecology and Reproductive Biology: X. 2019; 4: 100049. [DOI:10.1016/j.eurox.2019.100049] [PMID] []
89. Vizcaíno, M. A. C.; Corchado, A. R.; Cuadri, M. E. S. I.; Comadran, M. G.; Brassesco, M.; Carreras, R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women Reproductive biomedicine online. 2012; 24(6): 606-10. [DOI:10.1016/j.rbmo.2012.02.020] [PMID]
90. Domingo, J.; Guillén, V.; Ayllón, Y.; Martínez, M.; Muñoz, E.; Pellicer, A.; et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment Fertility and sterility. 2012; 97(4): 930-4. [DOI:10.1016/j.fertnstert.2012.01.093] [PMID]
91. Kim, J.; Turan, V.; Oktay, K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer The Journal of Clinical Endocrinology & Metabolism. 2016; 101(4): 1364-71. [DOI:10.1210/jc.2015-3878] [PMID] []
92. Oktay, K.; Hourvitz, A.; Sahin, G.; Oktem, O.; Safro, B.; Cil, A.; et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy The Journal of Clinical Endocrinology & Metabolism. 2006; 91(10): 3885-90. [DOI:10.1210/jc.2006-0962] [PMID]
93. Revelli, A.; Porcu, E.; Levi Setti, P.; Delle Piane, L.; Merlo, D.; Anserini, P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecological Endocrinology. 2013; 29(11): 993-6. [DOI:10.3109/09513590.2013.819083] [PMID]
94. Turan, V.; Bedoschi, G.; Moy, F.; Oktay, K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients Fertility and sterility. 2013; 100(6): 1681-5. [DOI:10.1016/j.fertnstert.2013.08.030] [PMID] []
95. Oktay, K. An individualized approach to fertility preservation in women with cancer The Journal of Supportive Oncology. 2006; 4(4): 181-2.
96. Azim, A. A.; Costantini-Ferrando, M.; Oktay, K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study Journal of Clinical Oncology. 2008; 26(16): 2630-5. [DOI:10.1200/JCO.2007.14.8700] [PMID]
97. Lambertini, M.; Fontanella, C. How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer? Breast cancer research and treatment. 2018; 168(3): 773-4. [DOI:10.1007/s10549-017-4654-1] [PMID]
98. Karalexi, M.A.; Kontogeorgi, A.; Papaioannou, G.; Neofytou, S.; Messaropoulos, P.; Moschovi, M.; et al. Fertility status in childhood cancer survivors of hematological malignancies: A systematic review. Hormones. 2023; 22: 211-21. [DOI:10.1007/s42000-023-00443-9] [PMID]
99. Blondeaux, E.; Massarotti, C.; Fontana, V.; Poggio, F.; Arecco, L.; Fregatti, P., et al. The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. Front. Oncol. 2021; 11: 690320. [DOI:10.3389/fonc.2021.690320] [PMID] []
100. Blumenfeld, Z. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. Clin. Med. Insights Reprod. Health. 2019; 13:1179558119870163. [DOI:10.1177/1179558119870163] [PMID] []
101. Balkenende, E.M.E.; Dahhan, T.; Beerendonk, C.C.M.; Fleischer, K.; Stoop, D.; Bos, A.M.E.; et al. Fertility preservation for women with breast cancer: A multicentre randomized controlled trial on various ovarian stimulation protocols. Hum. Reprod. 2022; 37: 1786-94 [DOI:10.1093/humrep/deac145] [PMID] []
102. Azim, H.A., Jr.; Peccatori, F.A.; de Azambuja, E.; Piccart, M.J. Motherhood after breast cancer: Searching for la dolce vita. Expert Rev. Anticancer Ther. 2011; 11: 287-98. [DOI:10.1586/era.10.208] [PMID]
103. Shalom-Paz, E.; Almog, B.; Shehata, F.; Huang, J.; Holzer, H.; Chian, R.-C.; et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod. Biomed. Online. 2010; 21: 566-71. [DOI:10.1016/j.rbmo.2010.05.003] [PMID]
104. Malacarne, E.; Devesa, M.; Martinez, F.; Rodriguez, I.; Coroleu, B. COH outcomes in breast cancer patients for fertility preservation: A comparison with the expected response by age. J. Assist. Reprod. Genet. 2020; 37: 3069-76. [DOI:10.1007/s10815-020-01944-x] [PMID] []
105. Laronda, M.M.; Rutz, A.L.; Xiao, S.; Whelan, K.A.; Duncan, F.E.; Roth, E.W.; et al. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nat. Commun. 2017; 8: 15261. [DOI:10.1038/ncomms15261] [PMID] []
ارسال پیام به نویسنده مسئول
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
